50 mg/m2 aldoxorubicin + 100 mg/m2 aldoxorubicin + 150 mg/m2 aldoxorubicin
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Kaposi's Sarcoma
Conditions
Kaposi's Sarcoma, HIV Positive, AIDS
Trial Timeline
Apr 3, 2014 → Apr 25, 2016
NCT ID
NCT02029430About 50 mg/m2 aldoxorubicin + 100 mg/m2 aldoxorubicin + 150 mg/m2 aldoxorubicin
50 mg/m2 aldoxorubicin + 100 mg/m2 aldoxorubicin + 150 mg/m2 aldoxorubicin is a phase 2 stage product being developed by ImmunityBio for Kaposi's Sarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02029430. Target conditions include Kaposi's Sarcoma, HIV Positive, AIDS.
What happened to similar drugs?
1 of 1 similar drugs in Kaposi's Sarcoma were approved
Approved (1) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02029430 | Phase 2 | Completed |
Competing Products
5 competing products in Kaposi's Sarcoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Selumetinib | AstraZeneca | Phase 1/2 | 24 |
| Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir | Merck | Approved | 43 |
| Maraviroc | Pfizer | Phase 2 | 35 |
| VEGF inhibitor PTC299 | PTC Therapeutics | Phase 1/2 | 21 |
| Tc 99m tilmanocept | Navidea Biopharmaceuticals | Phase 2 | 25 |